Phase 4 N=426 A Study for Type 2 Diabetic Patients
Type 2 Diabetes Mellitus
Primary: Change From Baseline to 48 Week Endpoint in Hemoglobin A1c (HbA1c) — -1.91; -1.87 percent (%) glycated hemoglobin — p=0.716
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=300 A Prospective Study to Evaluate the Safety of a New Trivalent Intranasal Influenza Vaccine
Influenza
Primary: Number of Subjects Reporting Fever — 3; 0 participants
Phase 4 N=65 Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment
HIV
Primary: Change From Baseline in Fasting Triglyceride (TG) Levels in the Lipid Evaluable (LE) Set at Week12 — 113.7; 114.2; 22.0; 8.1 milligram per deciliters (mg/dL)
Phase 4 N=134 Sertraline Pharmacotherapy for Alcoholism Subtypes
Alcoholism
Primary: Number of Days on Which Subjects Drank — 37.0; 33.8 days
Phase 4 N=104 Comparing Non-fixation of Mesh to Mesh Fixation in Laparoscopic Inguinal Hernia Repair
Inguinal Hernia
Primary: Recurrence of Inguinal Hernia on the Operated Side in Mesh Non-fixation and Mesh Fixation Group. — 0; 0 Participant
Phase 4 N=50 Comparison of Side Effects of Morphine and Hydromorphone Patient-Controlled Analgesia (PCA)
Post Operative Pain
Primary: Nausea Assessment by Patient — 4.6; 3.0 Units on a scale
Phase 4 N=33 Comparative Efficacy and Safety of Benzoyl Peroxide Used in Combination With Clindamycin vs. Benzoyl Peroxide Used in Combination With Clindamycin and Doxycycline in the Treatment of Moderate Acne
Acne
Primary: Percent Change in Inflammatory Acne Lesions From Baseline to Week 16 — -52.70; -48.84 Percent change
Phase 4 N=300 Study Comparing Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis in the Asia Pacific Region
Rheumatoid Arthritis
Primary: Change From Baseline in Adjusted Mean of American College of Rheumatology Response (ACR-N) Area Under Curve (AUC) Over 16 Weeks — 434.83; 289.54 Units on a scale…
Phase 4 N=1,392 A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40mg
Gastro-oesophageal Reflux
Primary: The Number of Patients With Complete Resolution of Heartburn by Week 4 — 272; 302; 278 participants — p=<0.05
Phase 4 N=72 Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis
Nail Psoriasis · Plaque Psoriasis
Primary: Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score for Target Fingernail — -4.32; -4.36 units on a scale — p=<0.0001
Phase 4 N=15 An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome
Irritable Bowel Syndrome
Primary: Abdominal Pain, as Determined by Daily Pain Diaries (Patterned After Item 3 From the Brief Pain Inventory; Cleeland and Ryan, 1994). — -1.5 Units on a scale — p=<0.001
Phase 4 N=460 Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis
Relapsing Remitting Multiple Sclerosis
Primary: Number of Participants Testing Positive for Neutralising Antibody (NAb) — 73 NAb+ participants
Phase 4 N=173 Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia Patients (0653A-172)(COMPLETED)
Hypercholesterolemia
Primary: The Percentage of Participants Achieving Low Density Lipoprotein-C (LDL-C) Treatment Goal After 6-week Treatment. — 90.4 Percentage of participants
Phase 4 N=8 Pharmacokinetics of Daptomycin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis (CVVHD)
Critically Ill · Hemodialysis
Primary: Daptomycin Transmembrane Clearance by Continuous Venovenous Hemodialysis — 6.3 mL/min
Phase 4 N=259 GORE EXCLUDER® Endoprosthesis - Low Permeability in Treatment of Abdominal Aortic Aneurysms
Aortic Aneurysm, Abdominal
Primary: Number of Subjects With Aneurysm Volume Increase Greater Than 10% at 2 Years Post-procedure — 9; 31 participants — p=<0.001